Roivant Sciences : 1Q 2022 Earnings Call Presentation

Financial Results and Business Update

for the Quarter Ended June 30, 2022

August 15, 2022

Forward-Looking Statements and Non-GAAP Financial Information

Forward-Looking Statements

This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forward- looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product candidates and any pending or potential litigation, including but not limited to our expectations regarding the outcome of any such litigation and costs and expenses associated with such litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned "Risk Factors" and "Forward-Looking

Statements" of our filings with the U.S. Securities and Exchange Commission,

available at www.sec.gov and investor.roivant.com. We operate in a very

competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Non-GAAP Financial Information

The discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). Additional information regarding non-GAAP financial measures can be found on slide 22 and in our earnings release furnished with our Current Report on Form 8-K dated August 15, 2022. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by U.S. GAAP, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies.

Disclaimer

Today's discussions and presentation are intended for the investor community

only; they are not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions.

2

Speakers

Matthew	Richard	Frank	Eric Venker, MD,	Mayukh
Gline	Pulik	Torti, MD	PharmD	Sukhatme, MD
Chief	Chief	Vant Chair	President and	President and
Executive Officer	Financial Officer		Chief Operating	Chief Investment
			Officer	Officer

3

Roivant's Potential Blockbuster Launch Ongoing and Further Growth Supported by Broad Pipeline, Discovery Engine, and Strong Capital Position

Commercial		Broad		Chip-to-clinic		Asymmetric		Strong
launch of		clinical-stage		discovery		upside		capital
VTAMA		pipeline		platform		potential		position
Potential blockbuster		Differentiated		Proprietary tools		Genevant IP portfolio		$2.0BN in cash, cash
in psoriasis with		pipeline programs		including QUAISAR		and deep scientific		equivalents and
additional		across multiple		and VantAI for atom-		expertise in nucleic		restricted cash as well
blockbuster upside		therapeutic areas; 10		by-atom simulation		acid delivery;		as additional public
potential in atopic		or more pivotal or		capabilities and		early-stage pipeline		and private holdings2
dermatitis1		pivotal-enabling		pipeline focused on		with promising
		trials expected by		challenging, high-		pre-clinical data
		end of calendar		value targets
		year 2022

1. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis.	4
2. As of June 30, 2022.

Strong Early VTAMA Prescriptions Positioned for Continued Growth

Approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch

Final Phase 3 psoriasis LTE data published in JAAD highlights

Weekly VTAMA Prescriptions1

mean 130 day remittive effect off-therapy for patients achieving

PGA=0

3,000

2,500

2,709 2,689

2,239

Dermavant's Japanese partner reported positive Phase 3 data for tapinarof for the treatment of atopic dermatitis, including statistically significant results on the IGA and EASI scores, and plans to submit for approval in Japan

Phase 3 atopic dermatitis readout expected in 1H 2023, expanding potential market to 15 million annual topical prescriptions in the US

2,000	1,829
1,500	1,343

		1,168
1,000	793	700
500	461

3 39

0

5/27 6/3 6/10 6/17 6/24 7/1 7/8 7/15 7/22 7/29 8/5

VTAMA Became the #1 Most Prescribed Branded Topical for Psoriasis Only 8 Weeks into Launch1

VTAMA has only received FDA approval for psoriasis, not atopic dermatitis.	5
1. Source: IQVIA.